Corvus Pharma

CORVUS PHARMACEUTICALS INC

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

CRVS

Biotech

News

Health Care

Movers

Trading Ideas

General

Corvus reported strong Phase 1 results for soquelitinib in atopic dermatitis, with early efficacy and no major safety concerns across all dose groups.

Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

Pinterest,Mobile,App,On,The,Screen,Smartphone,Iphone,Closeup.,Pinterest

Pre-Market Outlook

Markets

CETY

FIGS

GDOT

GMED

IOVA

JBIO

NCNA

PINS

PROF

SHPH

TMDX

VEEE

WOLF

WORX

ZKIN

Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

Analysts Pick 4 Stocks Poised for Growth, Including Tech Giants Microsoft And Meta

Initiation

Analyst Ratings

KOPN

NWFL

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharmaceuticals Inc

Press Releases

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Earnings

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Management

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

Abeona Therapeutics

Absci

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Astria Therapeutics

Benitec Biopharma

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

CytomX Therapeutics

Emergent BioSolutions

Gossamer Bio

Heron Therapeutics

Humacyte

ITeos Therapeutics

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prime Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Rezolute

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Solid Biosciences

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Vigil Neuroscience

XOMA Royalty

Mizuho

Oppenheimer

HC Wainwright & Co.

Ladenburg Thalmann

Comments

Corvus Pharma

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell